NRG Therapeutics

NRG Therapeutics is an innovative, privately held biotech founded in 2018, advancing a pipeline of CNS-penetrant small molecules that inhibit the mitochondrial permeability transition pore (mPTP). The company reached a key milestone in 2026 by initiating a first-in-human Phase 1 trial for its lead candidate, NRG5051, positioning it as a clinical-stage entity. With a focus on ALS and Parkinson's, NRG aims to address significant unmet medical need through a novel mechanism of action targeting a fundamental driver of neurodegeneration. The company benefits from experienced founders, leadership, and specialized investors in the neuroscience space.

Platform for discovering oral, CNS-penetrant small molecules that inhibit the mitochondrial permeability transition pore (mPTP) to rectify mitochondrial dysfunction, a key driver in neurodegeneration.

NRG operates in the competitive neurodegenerative disease space, facing large pharma and other biotechs. Its differentiation lies in its specific focus on mPTP inhibition, a mechanism distinct from most symptomatic therapies and other neuroprotective approaches. It competes with other companies targeting mitochondrial function, protein aggregation, and neuroinflammation.